Novo Nordisk Russia

Last updated: 13.02.2014

Address: Lomonosovsky Prospect 38, office 11, Moscow, 119330,Russia

Tel: +7 495 956-11-32


Company description

Novo Nordisk is a global healthcare company with 88 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs more than 30,000 employees in 76 countries, and markets its products in 179 countries.

Novo Nordisk products have been well-known for the Russian patients for more than 60 years. The representative office of the company was opened in Moscow in 1991 and currently there are more than 200 employees working in Russia.

The principles of corporate social responsibility are an integral part of the company’s worldwide development strategy. Novo Nordisk seeks to contribute to the development of diabetes care and improvement in peoples’ health in every country in which it operates. Thus Novo Nordisk has launched many well-known large-scale initiatives in Russia. Mobile Diabetes Centre designed and developed jointly with the Health Ministry of Russia and Endocrinology Research Center is one of the projects. During 2002-2009 it carried out twenty-four scientific and practical expeditions to various parts of Russia, and more than 23 thousand people were examined.

Novo Nordisk also helps endocrinologists from Russia and CIS countries to improve their skills and update their knowledge on diabetes treatment. Every year more than 1,200 doctors are trained in the Novo Nordisk Medical Education and Information Center based in Moscow.

Novo Nordisk actively collaborates with diabetes associations in Russia and the CIS and the International Diabetes Federation (IDF), which has repeatedly awarded the company as the best corporate partner. In 2004, Novo Nordisk joined forces with Russian diabetes associations to hold Diabetes Days in the Interparliamentary Assembly of Member Nations of the CIS and, from 2005 to 2009, in the State Duma and Council of Federations of Russia.

Novo Nordisk continues to mount campaigns, drawing attention to the problems of diabetes. In 2006, Novo Nordisk supported the international campaign which helped drive the adoption of a UN Resolution on diabetes and continues to play an active role in the implementation of the aims and tasks of this campaign. In 2008-2009 Novo Nordisk acted as a general partner of the International Forum “Unite to Change Diabetes” in Moscow and St. Petersburg Forum “Diabetes. It’s Time to Act”.

In 2010, Novo Nordisk signed an agreement to set up a high technology and fully GMP compliant production of modern insulin products on the territory of Russia. By doing this the company demonstrates its willingness to create benefits for people with diabetes in Russia and also to contribute to the development of an innovation based pharmaceutical industry in Russia in line with the State Pharma 2020 Strategy.

Products and services

Diabetes care, haemophilia care, growth hormone therapy and hormone replacement therapy.



We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here